REPRO-MED Systems, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Caitlin Cronin from Canaccord Genuity maintained a Buy rating on the stock and has a $5.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Caitlin Cronin’s rating is based on REPRO-MED Systems’ impressive financial performance and strategic growth initiatives. The company reported a significant increase in quarterly revenues, surpassing $10 million for the first time, and exceeded expectations across its profit and loss statement. This strong performance was driven by robust growth in both domestic and international markets, particularly in the subcutaneous immunoglobulin (SCIg) market, where the company has been gaining market share.
Cronin also highlights the company’s innovative pipeline, which includes multiple upcoming product submissions and new drug label additions that could significantly expand its market opportunities. Furthermore, REPRO-MED Systems is well-positioned to capitalize on the transition to pre-filled syringes in Europe, which presents a substantial growth opportunity. The company’s strategic focus on expanding its international presence and developing a next-generation pump to enhance its product offerings further supports the Buy rating, as these initiatives are expected to drive continued revenue growth and operational improvements.
In another report released today, Lake Street also reiterated a Buy rating on the stock with a $6.00 price target.
KRMD’s price has also changed moderately for the past six months – from $4.850 to $3.260, which is a -32.78% drop .